CF
LRMR icon

Corebridge Financial’s Larimar Therapeutics LRMR Stock Holding History

Corebridge Financial’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-20,609
Closed -$44.3K – 1560
2025
Q1 		$44.3K Sell
20,609
-306
-1% -$967 ﹤0.01% 2763
2024
Q4 		$80.9K Sell
20,915
-1,578
-7% -$10.4K ﹤0.01% 2651
2024
Q3 		$147K Sell
22,493
-139
-0.6% -$1.12K ﹤0.01% 2395
2024
Q2 		$164K Buy
+22,632
New +$173K ﹤0.01% 2322

Other funds holding LRMR

DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Corebridge Financial's LRMR Position: Q2 2025 in Review

Corebridge Financial sold out of Larimar Therapeutics (LRMR) in Q2 2025, closing a stake of 20,609 shares — an estimated $44.3K sold.

Corebridge Financial first reported a position in LRMR in Q2 2024 and held it in 4 quarters. The position peaked at $164K in Q2 2024. 116 funds tracked by Wall St. Rank hold LRMR as of Q2 2025.

  • Corebridge Financial reported no remaining Larimar Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Corebridge Financial sold 20,609 Larimar Therapeutics shares in Q2 2025, an estimated $44.3K.
  • Corebridge Financial first reported a position in Larimar Therapeutics in Q2 2024 and held it in 4 quarters.
  • Corebridge Financial's Larimar Therapeutics position peaked at $164K in Q2 2024.
  • 116 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q2 2025.

Based on Corebridge Financial's 13F filing for Q2 2025, filed 12 Aug 2025.